摘要
目的探讨甲状腺球蛋白抗体（TGAb）和甲状腺过氧化物酶抗体（TPOAb）水平与Graves病患者治疗后甲状腺功能减退发生率的关系。方法选取325例治疗前TGAb、TPOAb阴性Graves病患者，分别于^131I治疗后3、6、12、18个月测定血清游离三碘甲腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺素（TSH）、TGAb、TPOAb水平，以18个月时血清TGAb、TPOAb水平分为TGAb、TPOAb阴性组和TGAb、TPOAb阳性组，比较两组甲状腺功能减退的发生率。结果TGAb、TPOAb阴性组271例；TGAb、TPOAb阳性组54例。甲状腺功能减退发生率为7．4％（24／325），其中TGAb、TPOAb阴性组甲状腺功能减退发生率为3．0％（8／271），TGAb、TPOAb阳性组为29．6％（16154），两组比较差异有统计学意义（P〈0．05）。结论Graves病^131I治疗后TGAb、TPOAb水平与甲状腺功能减退发生率显著相关，治疗后动态检测TGAb、TPOAb水平对指导临床、判断预后有重要意义。
Objective To investigate the correlation between serum levels of thyroglobulin antibody （TGAb）, thyroid peroxidase antibody （TPOAb） and hypothyroidism incidence in Graves disease after ^131I therapy. Methods Three hundred and twenty-five patients with Graves disease whose TGAb and TPOAb were negative before treatment were selected. Serum levels of FT3,Ft4,TSH,TGAb and TPOAb were measured at the 3rd,6th, 12th and 18th month after treatment respectively. All cases were divided into positive group and negative group according to the serum levels of TGAb and TPOAb at the 18th month after ^131I treatment. The hypothyroidism incidences of two groups were compared. Results There were 271 cases in negative group and 54 cases in positive group. The hypothyroidism incidence was 7.4%（24/325）, and the incidence of negative group was 3.0% （8/271）,while the incidence of positive group was 29.6% （16/54）. There was significant difference between two groups （P 〈 0.05）. Conclusions Hypothyroidism incidence of Graves disease after ^131I therapy has obvious correlation with the serum levels of TGAb and TPOAb. Dynamic observation of the serum levels of TGAb and TPOAb in Graves disease after ^131I therapy has important significance for clinical guiding and prognosis judgement.
出处
《中国医师进修杂志》
2012年第16期11-14,共4页
Chinese Journal of Postgraduates of Medicine
